<abstract xmlns="http://www.w3.org/1999/xhtml"><p> In the past years there have been numerous discoveries regarding treatment of patients with HIV. If at first the doctors watched as patients live longer, now we want these patients to live better with regimens potent, safe, individualized and without side effects. HAART has revolutionized “the world HIV” and caused a significant reduction in mortality, and morbidity associated with HIV-related opportunistic infections. However, side effects associated with HAART, metabolic toxicity (such as abnormal fat distribution, abnormal lipid and glucose metabolism, and bone loss) and the large number of pills led to decreased patient adherence.</p></abstract>

In the past years there have been numerous discoveries regarding treatment of patients with HIV. If at first the doctors watched as patients live longer, now we want these patients to live better with regimens potent, safe, individualized and without side effects. HAART has revolutionized “the world HIV” and caused a significant reduction in mortality, and morbidity associated with HIV-related opportunistic infections. However, side effects associated with HAART, metabolic toxicity (such as abnormal fat distribution, abnormal lipid and glucose metabolism, and bone loss) and the large number of pills led to decreased patient adherence.

DOLUTEGRAVIR efficacy in HIV infected patients

Ovidius University, Clinical Infectious Diseases Hospital Constanta, Romania

ARS Medica Tomitana

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"DOLUTEGRAVIR efficacy in HIV infected patients"}

In the past years there have been numerous discoveries regarding treatment of patients with HIV. If at first the doctors watched as patients live longer, now...

DOLUTEGRAVIR efficacy in HIV infected patients

Publié en ligne: 09 mai 2015

Pages: 42 - 51

DOI: https://doi.org/10.1515/arsm-2015-0019

Mots clés
Dolutegravir, HAART, efficacy, resistance, safety

© by Irina Magdalena Dumitru

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

DOLUTEGRAVIR efficacy in HIV infected patients

Publié en ligne: 09 mai 2015

Pages: 42 - 51

DOI: https://doi.org/10.1515/arsm-2015-0019

Mots clésDolutegravir, HAART, efficacy, resistance, safety

© by Irina Magdalena Dumitru

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mots clés
Dolutegravir, HAART, efficacy, resistance, safety